Core Viewpoint - ProSomnus, Inc. is positioned to support patients with Obstructive Sleep Apnea (OSA) following the discontinuation of many OSA devices by Philips Respironics, which has affected approximately 4 million patients [1][2] Group 1: Company Positioning - ProSomnus offers precision intraoral devices that have shown excellent efficacy, adherence, and patient preference in clinical studies, including comparisons with CPAP devices [2] - The company connects sleep physicians with local providers who accept medical insurance and Medicare, ensuring high patient satisfaction [2] - ProSomnus is prepared to facilitate access to healthcare for millions of untreated OSA patients, emphasizing the safety and effectiveness of its devices based on scientific data from numerous studies [2] Group 2: Industry Implications - The exit of Philips Respironics from the U.S. sleep business creates a significant gap in the market, necessitating collaboration between healthcare providers and Dental Sleep Medicine (DSM) specialists to offer alternative treatment options [2][3] - Oral Appliance Therapy (OAT) is highlighted as a highly effective, non-invasive alternative to traditional CPAP therapy, particularly for patients with less severe OSA [2][3] - The discontinuation of CPAP devices is expected to lead to supply chain issues, affecting patient access to care, which ProSomnus aims to address with its precision appliances [2][3] Group 3: Market Context - OSA affects over 1 billion people globally and is associated with serious comorbidities such as heart failure, stroke, and type 2 diabetes [3] - ProSomnus devices are FDA-cleared, patented, and covered by various medical insurance plans, representing over 200 million covered lives [3][4]

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading symbol Name of Exchange on which registered Common Stock, par value $0.0001 per share OSA The Nasdaq Global Market Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share OSAAW The Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ...

Table of Contents OSAAW The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41567 ProSomnus, Inc. (Exact name of registrant as specified in its charter) ...

Table of Contents Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share OSAAW The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41567 PROSOMNUS, INC. (Exact name of registrant as specified in its charter) Delaware 88-2978216 (State of Other Jurisdiction ...